Exploring associations between diurnal cortisol, stress, coping and psychopathology in adolescents and young adults with 22q11.2 deletion syndrome.
Coping strategies
Diurnal cortisol
HPA-Axis
Psychopathology
Psychosis
Stress exposure
Journal
Comprehensive psychoneuroendocrinology
ISSN: 2666-4976
Titre abrégé: Compr Psychoneuroendocrinol
Pays: England
ID NLM: 101774169
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
28
10
2021
accepted:
10
12
2021
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
22q11.2 deletion syndrome (22q11DS) is a neurogenetic condition associated to a high risk for psychiatric disorders, including psychosis. Individuals with 22q11DS are thought to experience increased levels of chronic stress, which could lead to alterations in hypothalamic-pituitary-adrenocortical (HPA)-axis functioning. In the current study, we investigated for the first time diurnal salivary cortisol profiles in adolescents and young adults with 22q11DS as well as their link with stress exposure, coping strategies and psychopathology, including psychotic symptoms. Salivary cortisol was collected from adolescents and young adults with 22q11DS ( We observed similar daily levels and diurnal profiles of salivary cortisol in adolescents and young adults with 22q11DS compared to HCs. However, participants with 22q11DS reported less frequent exposure to stress than HCs. In 22q11DS, we observed a significant association between the use of non-adaptive coping strategies and the severity of psychotics symptoms. Cortisol level was not associated to severity of psychotic symptoms, but elevated cortisol awakening response (CAR) was found in participants with 22q11DS with higher levels of general psychopathology. Our results do not support earlier propositions of altered HPA-axis functioning in 22q11DS but highlight the need to further investigate diurnal cortisol as an indicator of HPA-axis functioning and its link with (earlier) stress exposure and psychopathology in this population. Interventions should target the development of adaptive coping skills in preventing psychosis in 22q11DS.
Sections du résumé
Background
UNASSIGNED
22q11.2 deletion syndrome (22q11DS) is a neurogenetic condition associated to a high risk for psychiatric disorders, including psychosis. Individuals with 22q11DS are thought to experience increased levels of chronic stress, which could lead to alterations in hypothalamic-pituitary-adrenocortical (HPA)-axis functioning. In the current study, we investigated for the first time diurnal salivary cortisol profiles in adolescents and young adults with 22q11DS as well as their link with stress exposure, coping strategies and psychopathology, including psychotic symptoms.
Methods
UNASSIGNED
Salivary cortisol was collected from adolescents and young adults with 22q11DS (
Results
UNASSIGNED
We observed similar daily levels and diurnal profiles of salivary cortisol in adolescents and young adults with 22q11DS compared to HCs. However, participants with 22q11DS reported less frequent exposure to stress than HCs. In 22q11DS, we observed a significant association between the use of non-adaptive coping strategies and the severity of psychotics symptoms. Cortisol level was not associated to severity of psychotic symptoms, but elevated cortisol awakening response (CAR) was found in participants with 22q11DS with higher levels of general psychopathology.
Conclusions
UNASSIGNED
Our results do not support earlier propositions of altered HPA-axis functioning in 22q11DS but highlight the need to further investigate diurnal cortisol as an indicator of HPA-axis functioning and its link with (earlier) stress exposure and psychopathology in this population. Interventions should target the development of adaptive coping skills in preventing psychosis in 22q11DS.
Identifiants
pubmed: 35755923
doi: 10.1016/j.cpnec.2021.100103
pii: S2666-4976(21)00077-1
pmc: PMC9216249
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100103Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
None.
Références
Schizophr Bull. 2011 Mar;37(2):432-41
pubmed: 19734244
Psychoneuroendocrinology. 2020 Mar;113:104540
pubmed: 31958652
J Neurodev Disord. 2020 Nov 13;12(1):30
pubmed: 33187471
J Autism Dev Disord. 2017 Apr;47(4):992-1005
pubmed: 28083777
Psychosom Med. 2006 Jan-Feb;68(1):41-50
pubmed: 16449410
Biol Psychiatry. 2013 Sep 15;74(6):410-7
pubmed: 23562006
J Neurodev Disord. 2011 Mar;3(1):68-75
pubmed: 21475728
J Genet Psychol. 2015 Jan-Apr;176(1-2):93-109
pubmed: 25775213
Acta Psychiatr Scand. 2007 Aug;116(2):137-44
pubmed: 17650276
J Intellect Disabil Res. 2007 Sep;51(Pt 9):666-70
pubmed: 17845235
Psychoneuroendocrinology. 2016 Jan;63:414-32
pubmed: 26563991
Dev Psychobiol. 2012 Jul;54(5):493-502
pubmed: 21953537
Neurosci Biobehav Rev. 2016 Sep;68:157-166
pubmed: 27229759
Sch Psychol Q. 2012 Dec;27(4):210-222
pubmed: 23294235
Schizophr Bull. 2003;29(4):703-15
pubmed: 14989408
Am J Med Genet A. 2017 May;173(5):1301-1308
pubmed: 28421700
Psychoneuroendocrinology. 2005 Sep;30(8):744-52
pubmed: 15919580
Clin Psychol Rev. 2007 May;27(4):409-24
pubmed: 17222489
Dev Psychopathol. 2013 Aug;25(3):629-42
pubmed: 23880381
Pediatrics. 2009 May;123(5):e871-7
pubmed: 19403480
Br J Psychiatry. 2010 Nov;197(5):378-85
pubmed: 21037215
J Child Psychol Psychiatry. 2018 Apr;59(4):327-346
pubmed: 28714126
J Clin Res Pediatr Endocrinol. 2008;1(1):43-8
pubmed: 21318064
Arch Gen Psychiatry. 2009 May;66(5):527-36
pubmed: 19414712
J Pediatr Genet. 2016 Sep;5(3):150-7
pubmed: 27617156
Psychoneuroendocrinology. 2019 Aug;106:85-94
pubmed: 30959234
Nat Rev Neurosci. 2008 Dec;9(12):947-57
pubmed: 19002191
Nat Rev Neurosci. 2009 Jun;10(6):434-45
pubmed: 19401723
Schizophr Bull. 2003;29(4):671-92
pubmed: 14989406
Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):17058-63
pubmed: 17075058
Front Psychiatry. 2017 Apr 20;8:55
pubmed: 28473776
Horm Behav. 2011 Aug;60(3):301-5
pubmed: 21722644
Am J Psychiatry. 2014 Jun;171(6):627-39
pubmed: 24577245
Psychosom Med. 2010 May;72(4):340-7
pubmed: 20190128
J Adolesc. 1987 Jun;10(2):163-86
pubmed: 3611466
Biol Psychol. 2009 Mar;80(3):265-78
pubmed: 19022335
World Psychiatry. 2016 Oct;15(3):259-265
pubmed: 27717277
Early Interv Psychiatry. 2018 Aug;12(4):525-534
pubmed: 29761632
Psychoneuroendocrinology. 2017 Sep;83:25-41
pubmed: 28578301
Psychol Med. 2011 Nov;41(11):2305-15
pubmed: 21733219
Pediatr Res. 1995 Apr;37(4 Pt 1):502-6
pubmed: 7596692
N Engl J Med. 1998 Jan 15;338(3):171-9
pubmed: 9428819
Neurosci Biobehav Rev. 2017 Feb;73:191-218
pubmed: 27993603
Biol Psychiatry. 1996 Jul 15;40(2):79-88
pubmed: 8793040
Schizophr Bull. 2018 Oct 15;44(suppl_2):S525-S535
pubmed: 29548017
J Psychiatr Res. 2019 Jul;114:99-104
pubmed: 31054456
Psychol Rev. 1997 Oct;104(4):667-85
pubmed: 9337628